Can Candel Therapeutics Repeat Its Earnings Beat Without Burning More Cash?

Candel Therapeutics Inc (CADL) reports second-quarter 2026 earnings on August 13, 2026, with analysts expecting another quarterly loss as the clinical-stage biotech continues advancing its oncolytic viral immunotherapy pipeline. The central question: can CADL demonstrate meaningful clinical progress and capital efficiency to justify its recent rally, or will mounting losses and cash burn concerns weigh on sentiment? With the stock up 58% year-to-date and trading well above all major moving averages, investors are pricing in optimism that may leave little room for disappointment.

Part 1: Earnings Preview

Candel Therapeutics is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for the treatment of cancer, with lead programs targeting pancreatic cancer, lung cancer, and prostate cancer. The company's proprietary platform combines engineered viruses designed to selectively infect and kill cancer cells while stimulating anti-tumor immune responses.

For the second quarter ending June 2026, analysts expect CADL to report a loss of $-0.22 per share based on consensus from 4 analysts, with estimates ranging from $-0.16 to $-0.26. The company most recently reported first-quarter 2026 EPS of $-0.14, beating estimates of $-0.22 by 36.36%. Year-over-year, the Q2 2026 estimate of $-0.22 represents a 144% increase in losses compared to the $-0.09 reported in Q2 2025, reflecting accelerated clinical trial spending and operational expansion.

Three key themes define this earnings story:

Clinical Trial Progress and Data Readouts: Investors will scrutinize updates on patient enrollment, trial timelines, and any preliminary efficacy or safety signals from ongoing studies. Any advancement toward pivotal trial initiation or regulatory milestones could validate the company's platform and justify current valuations.

Cash Runway and Capital Allocation: With widening losses expected, management's commentary on cash burn rate, remaining runway, and financing strategy will be critical. The market will want assurance that CADL can fund operations through key clinical milestones without dilutive near-term financing.

Partnership and Commercialization Strategy: Any announcements regarding strategic collaborations, licensing agreements, or plans to monetize earlier-stage assets could provide non-dilutive funding sources and validate the platform's commercial potential.

Analyst commentary ahead of the release reflects cautious optimism tempered by execution risk. The 8 Strong Buy ratings and $20.00 mean price target (87% upside from current levels) suggest the Street sees significant long-term value, but the wide estimate range for 2027 ($-1.94 to $0.35) underscores uncertainty around the path to profitability and the binary nature of clinical development outcomes.

Part 2: Historical Earnings Performance

CADL's recent earnings history reveals significant volatility in both results and estimate accuracy. Over the past four quarters, the company has alternated between substantial beats and misses, with surprise percentages ranging from +47.06% to -125.00%.

The most recent quarter (Q1 2026) delivered a strong beat, with reported EPS of $-0.14 versus estimates of $-0.22, representing a 36.36% positive surprise. This followed a disastrous Q4 2025 result where CADL reported $-0.54 against expectations of $-0.24, missing by 125% — the worst performance in the dataset. Prior to that, Q3 2025 saw a modest 23.53% miss ($-0.21 vs. $-0.17), while Q2 2025 produced a 47.06% beat ($-0.09 vs. $-0.17).

The pattern suggests limited predictability and high execution risk, with quarterly results heavily dependent on the timing of clinical trial expenses, milestone payments, and one-time charges. The dramatic Q4 2025 miss appears to have been an outlier driven by accelerated spending, but the inconsistency makes it difficult to establish a reliable trend. Investors should approach this release with caution given the historical unpredictability.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

CADL's earnings releases have historically occurred after market close, meaning Day 0 reflects anticipatory trading before results are known, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around earnings shows moderate volatility with mixed directional bias. The stock has averaged an absolute Day 0 move of 3.63% with an intraday range of 8.32%, while Day +1 has seen larger moves averaging 5.26% with ranges of 9.25%.

The most recent earnings (May 2026) produced minimal Day 0 movement (-0.34%) but a wider intraday range (11.19%), followed by a modest Day +1 decline of 1.57%. This contrasts sharply with earlier releases: the March 2026 report saw a 6.22% Day +1 decline despite a small Day 0 move, while the March 2025 report delivered a dramatic 10.20% Day +1 surge after minimal Day 0 action.

The data suggests Day +1 tends to produce the more significant directional move as investors digest results and management commentary, with post-earnings sessions frequently exceeding 5% moves in either direction. Given the current 3.18% expected move from options pricing, the market may be underestimating potential volatility based on historical patterns.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 3.18% (±$0.34) for the upcoming earnings release, which sits below both the historical Day 0 average of 3.63% and well below the Day +1 average of 5.26%. This suggests options traders may be underpricing potential volatility, particularly given CADL's tendency for larger follow-through moves in the session after results are released.

Part 3: What Analysts Are Saying

Analyst sentiment on CADL is overwhelmingly bullish, with the stock carrying an average recommendation of 4.60 out of 5.00 — firmly in Strong Buy territory. The consensus includes 8 Strong Buy ratings and 2 Hold ratings among 10 analysts covering the stock, with zero sell-side recommendations.

The mean price target of $20.00 implies 87% upside from the current price of $10.68, with individual targets ranging from a low of $9.00 (16% downside) to a high of $26.00 (143% upside). This wide range reflects divergent views on the company's clinical and commercial prospects, though the clustering of Strong Buy ratings suggests most analysts see the risk/reward as favorable at current levels.

Sentiment has improved over the past month, with Strong Buy ratings increasing from 7 to 8 while Hold ratings remained steady at 2. The average recommendation ticked up from 4.56 to 4.60, indicating growing analyst confidence. This strengthening conviction comes despite the company's widening expected losses, suggesting analysts are looking past near-term cash burn to focus on longer-term clinical value creation and potential inflection points in the pipeline.

Part 4: Technical Picture

CADL enters earnings with exceptionally strong technical momentum and a maximum-strength buy signal. The Barchart Technical Opinion stands at 100% Buy, unchanged from both one week ago and one month ago, reflecting sustained bullish conviction across all timeframes.

Timeframe Analysis:

• Short-term (100% Buy): Maximum buy signal indicates powerful near-term momentum heading into the earnings release
• Medium-term (100% Buy): Continued strength in the intermediate timeframe suggests the uptrend is well-established beyond just short-term speculation
• Long-term (100% Buy): Maximum long-term buy signal reflects a fundamental shift in the stock's technical structure and trend direction

Trend Characteristics: The signal strength is at Maximum levels and the direction is Strengthening, indicating CADL is in a robust uptrend with accelerating positive momentum as it approaches earnings.

The stock is trading at $10.68, positioned above all key moving averages: the 5-day ($10.60), 10-day ($10.39), 20-day ($10.10), 50-day ($9.55), 100-day ($8.07), and 200-day ($6.74). This complete alignment with the stock above every major moving average is a textbook bullish setup, though it also means there are no nearby technical support levels if the earnings reaction disappoints.

The technical picture is highly supportive but potentially overextended heading into earnings. With the stock up 58% year-to-date and trading 58% above its 200-day moving average, much positive news may already be priced in. The nearest support level sits at the 20-day moving average around $10.10, representing a 5.4% cushion, while the 50-day at $9.55 provides secondary support. Any disappointment on clinical progress, cash burn guidance, or forward estimates could trigger profit-taking from a technically stretched position, while a positive surprise could fuel further momentum given the strong trend structure and maximum buy signals across all timeframes.